Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth (Status and Outlook) 2023-2029

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth (Status and Outlook) 2023-2029

Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized as a low or unpredictable level of alpha-1 protein, generated by liver. The disease most commonly affects lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AATD, and includes various preparations derived from pooled human plasma.

LPI (LP Information)' newest research report, the “Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Forecast” looks at past sales and reviews total world Alpha-1 Antitrypsin Deficiency Augmentation Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Alpha-1 Antitrypsin Deficiency Augmentation Therapy sales for 2023 through 2029. With Alpha-1 Antitrypsin Deficiency Augmentation Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alpha-1 Antitrypsin Deficiency Augmentation Therapy industry.

This Insight Report provides a comprehensive analysis of the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Alpha-1 Antitrypsin Deficiency Augmentation Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alpha-1 Antitrypsin Deficiency Augmentation Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy.

The global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Alpha-1 Antitrypsin Deficiency Augmentation Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Alpha-1 Antitrypsin Deficiency Augmentation Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Alpha-1 Antitrypsin Deficiency Augmentation Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Alpha-1 Antitrypsin Deficiency Augmentation Therapy players cover Grifols, CSL, Baxter, Kamada, Takeda and Abeona, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Alpha-1 Antitrypsin Deficiency Augmentation Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Glassia
Aralast NP
Prolastin C
Others

Segmentation by application
Hospitals
Specialty Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Grifols
CSL
Baxter
Kamada
Takeda
Abeona

Please note: The report will take approximately 2 business days to prepare and deliver.